Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Breast cancer, female
Stage/Subtype:  stage I breast cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 67 for your search:
Start Over
Safety and Efficacy Study of the Xoft® Axxent® eBx™ IORT System
Phase: Phase IV
Type: Treatment
Age: 40 and over
Trial IDs: CTPR-0009, NCI-2013-01601, NCT01644669
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: BO25126, NCI-2012-00351, 2010-022902-41, BIG 04-11, TOC4939G, NCT01358877
Testosterone in Treating Postmenopausal Patients with Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: A221102, NCI-2012-00719, CDR0000730083, CALGB-A221102, NCCTG-N10C7, NCT01573442
Hormone Therapy with or without Everolimus in Treating Patients with Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1207, NCI-2012-01995, CDR0000738280, SWOG-S1207, NCT01674140
Standard or Comprehensive Radiation Therapy in Treating Patients with Early-Stage Breast Cancer Previously Treated with Chemotherapy and Surgery
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NSABP-B-51/RTOG-1304, NCI-2012-03198, NSABP PROTOCOL B-51/RTOG PROTOCOL 1304, NSABP-B-51, NCT01872975
Lymph Node Dissection and Radiation Therapy in Treating Patients with Breast Cancer Previously Treated with Chemotherapy and Surgery
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: A011202, NCI-2013-00875, NCT01901094
Olaparib in Treating Patients with Triple-Negative Non-metastatic Breast Cancer Who Have Completed Definitive Local Treatment and Chemotherapy
Phase: Phase III
Type: Natural history/Epidemiology, Treatment
Age: 18 and over
Trial IDs: NSABP-B-55, NCI-2014-00644, BIG 6-13, D081CC00006, NCT02032823
Carboplatin and Accelerated Radiation Therapy in Treating Patients with Stage I-II Triple-Negative Breast Cancer Previously Treated with Surgery
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: NYU 10-01969, NCI-2011-00198, 10-01969, NCT01289353
Single Fraction High-Gradient Partial Breast Irradiation in Treating Patients With Low-Risk Stage 0-I Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 50 and over
Trial IDs: 201401160, NCI-2014-00269, NCT02076074
Docetaxel and Cyclophosphamide in Treating Patients with Hormone-Receptor Positive Early Stage Breast Cancer Undergoing Surgery
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: WCI 1505-08, NCI-2011-03383, NCT00832338
Accelerated Whole Breast Radiotherapy in Treating Patients with Breast Cancer Who Have Undergone Surgery
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 040807, NCI-2012-00535, CDR0000643276, CINJ-040807, NCT00909909
Sorafenib Tosylate, Cisplatin, and Paclitaxel before Surgery in Treating Patients with Stage I-IIIA Breast Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: WCI1590-08, NCI-2011-03389, NCT01194869
Radiation Therapy in Treating Patients With Breast Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2009-0818, NCI-2011-01102, NCT01245712
Biological Therapy in Improving Immune Reconstitution after Chemotherapy in Older Patients with Stage I-III Breast, Stage II Bladder, or Stage II-III Colorectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: 11-C-0146, NCI-2013-01487, 110146, P09590, NCT01339000
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 368255, NCI-2015-00026, 1137008 / 20130058, NCT01570036
Cisplatin or Doxorubicin Hydrochloride and Cyclophosphamide before Surgery in Treating Patients with Newly Diagnosed Breast Cancer and BRCA Mutations
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-258, NCI-2012-02217, TBCRC031, NCT01670500
Paclitaxel and Cyclophosphamide with or without Trastuzumab before Surgery in Treating Patients with Previously Untreated Stage I-III Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 264-12, NCI-2012-01372, NCT01750073
Radiation Therapy in Treating Post-Menopausal Women with Early Stage Breast Cancer Undergoing Surgery
Phase: Phase II
Type: Treatment
Age: 50 and over
Trial IDs: I 108907, NCI-2009-01568, NCT01754519
Digoxin in Treating Patients With Stage I-III Breast Cancer Planning to Undergo Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: SKCCC J1232, NCI-2013-00513, A-17427, J1232, NA_00072292, NCT01763931
Paclitaxel, Trastuzumab, and Pertuzumab before Surgery in Treating Patients with Inflammatory Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-497, NCI-2013-01110, ML28193, NCT01796197
Oral CDB-4124 vs. Placebo in Stage 0-II Primary Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 12B09, NCI-2012-03189, STU00074599, NCT01800422
Start Over